iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) had a great day in the market Friday, trading on gains of more than 24% at the close. However, this is likely just the tip of the iceberg with a big run just ahead. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Why Investors Are Excited About IBIO Stock

iBio is one of a long list of companies that is working to produce a viable COVID-19 vaccine. However, while there are many companies in this race, few actually have anything of substance. IBIO is one of these few.

The company is currently working on multiple coronavirus vaccine candidates in a partnership with CC Pharming. This is important as CC Pharming has been successful in developing a vaccine for a sister strain of the coronavirus that causes COVID-19.

While the fact that the company is working on a potential vaccine, that’s not the only reason to be excited here. In fact, a major point of inflection for the stock is the company’s FastPharming Facility.

The facility was developed using grant funding with the goal of being prepared in the face of a pandemic. The idea of the facility was to be able to produce vaccines and other biological agents to fight against pandemics at an incredibly fast pace.

In fact, should the company’s vaccine development end in a vaccine that is effective, it will be able to produce the vaccine in mass doses very quickly. That’s a big advantage for IBIO.

Think about it. Sure, several companies are working to create a vaccine. However, once that vaccine is created, they are going to need to manufacture massive amounts of the vaccine in order to commercialize. So, throughout development, most companies have to work twice as hard to create a manufacturing process.

IBIO simply doesn’t have that problem. The company’s FastPharming facility means that as soon as its vaccine is developed, it is ready to mass-manufacture the vaccine and send it out for commercialization.

That’s exciting!

Moreover, money isn’t an issue for iBio either. The company has a deal with Lincoln Park where it is able to draw up to $50 million over the course of three years. That $50 million gives the company plenty of cash to move through development.

Of course, it may not have to use the cash in the development of its COVID-19 vaccine. After all, grant funding is all over the place at the moment, and IBIO is highly likely to get its share.

Catalysts Ahead

It’s important to keep in mind that iBio has several catalysts ahead. First and foremost, as the company works on the COVID-19 vaccine, it will have data to report, regulatory updates, and more. Each time one of these reports break, the stock is likely to fly!

Moreover, as we get closer to potential regulatory approval, we’re likely to see more conversation about the FastPharming facility and manufacturing mass amounts of the vaccine. As these conversations arise, they will likely act as catalysts, sending the stock higher. All in all, IBIO is a stock that should be paid attention to.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.